Small-Molecule Cyclophilin Inhibitors Potently Reduce Platelet Procoagulant Activity
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24087163 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Jens Van Bael und 10 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Thrombosis Research, KU Leuven Kulak Kortrijk Campus, 8500 Kortrijk, Belgium. Hauptthemen laut MEDLINE: Cyclophilins, Thrombosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: KU Leuven.
Abstract (Originalsprache)
Procoagulant platelets are associated with an increased risk for thrombosis. Procoagulant platelet formation is mediated via Cyclophilin D (CypD) mediated opening of the mitochondrial permeability transition pore. Inhibiting CypD activity could therefore be an interesting approach to limiting thrombosis. In this study, we investigated the potential of two novel, non-immunosuppressive, non-peptidic small-molecule cyclophilin inhibitors (SMCypIs) to limit thrombosis in vitro, in comparison with the cyclophilin inhibitor and immunosuppressant Cyclosporin A (CsA). Both cyclophilin inhibitors significantly decreased procoagulant platelet formation upon dual-agonist stimulation, shown by a decreased phosphatidylserine (PS) exposure, as well as a reduction in the loss of mitochondrial membrane potential. Furthermore, the SMCypIs potently reduced procoagulant platelet-dependent clotting time, as well as fibrin formation under flow, comparable to CsA. No effect was observed on agonist-induced platelet activation measured by P-selectin expression, as well as CypA-mediated integrin αIIbβ3 activation. Importantly, whereas CsA increased Adenosine 5′-diphosphate (ADP)-induced platelet aggregation, this was unaffected in the presence of the SMCypIs. We here demonstrate specific cyclophilin inhibition does not affect normal platelet function, while a clear reduction in procoagulant platelets is observed. Reducing platelet procoagulant activity by inhibiting cyclophilins with SMCypIs forms a promising strategy to limit thrombosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory for Thrombosis Research, KU Leuven Kulak Kortrijk Campus, 8500 Kortrijk, Belgium.
- Team Viruses, Hepatology Cancer, INSERM U955, 94000 Creteil, France.
- Centre de Biologie Structurale (CBS), INSERM U1054, CNRS UMR5048, Université de Montpellier, 34090 Montpellier, France.
- National Reference Center for Viral Hepatitis B, C and Delta, Department of Virology, Hôpital Henri Mondor, Université Paris-Est, 94000 Creteil, France.
- Diagnostic Laboratory Research, UMC Utrecht, 3584 CX Utrecht, The Netherlands.
ORCID-Profile: Jens Van Bael, Abdelhakim Ahmed-Belkacem, Arjan D Barendrecht, Coen Maas, Claudia Tersteeg
Förderung
- KU Leuven
Zitieren
APA
Van Bael, J., Vandenbulcke, A., Ahmed-Belkacem, A., Guichou, J. F., Pawlotsky, J. M., Samyn, J., Barendrecht, A. D., Maas, C., De Meyer, S. F., Vanhoorelbeke, K., & Tersteeg, C. (2023). Small-Molecule Cyclophilin Inhibitors Potently Reduce Platelet Procoagulant Activity. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24087163
Vancouver
Van Bael J, Vandenbulcke A, Ahmed-Belkacem A, Guichou JF, Pawlotsky JM, Samyn J, et al. Small-Molecule Cyclophilin Inhibitors Potently Reduce Platelet Procoagulant Activity. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24087163
BibTeX
@article{VanBael2023,
author = {Van Bael, Jens and Vandenbulcke, Aline and Ahmed-Belkacem, Abdelhakim and Guichou, Jean-François and Pawlotsky, Jean-Michel and Samyn, Jelle and Barendrecht, Arjan D and Maas, Coen and De Meyer, Simon F and Vanhoorelbeke, Karen and Tersteeg, Claudia},
title = {Small-Molecule Cyclophilin Inhibitors Potently Reduce Platelet Procoagulant Activity},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24087163}
}
EUVIMED